anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Current NSV treatments can be considered suboptimal and leading to decreased patient's quality of life due to the emotional burden of therapy dissatisfaction. When a stable NSV is not responding to medical therapy, surgery may be a useful treatment approach. All surgical techniques in vitiligo treatment share the same principle: transferring autologous melanocytes from a donor to repopulate melanocytes in the depigmented area that lacks a reservoir or fails to activate melanocytes in the outer root sheath (ORS) of hair follicles. MPG as the most frequently performed tissue transplantation technique transferred the epidermal melanocyte to vitiligo lesion, while NCEHFORSCS provides melanocytes with better properties and contains melanocyte stem cells. The advantages of melanocytes from ORS compared to epidermal are the follicular melanocyte:keratinocyte ratio consists of one melanocyte for every five keratinocytes or 1:5 in the hair bulb, melanocytes are more dendritic, have larger melanosomes, and have the potential to produce more melanin pigment. Due to these properties, hair follicles can be a better source of melanocytes than epidermis in the delivery of cellular transplantation-based therapy for vitiligo therapy. Research comparing the effectiveness of the two procedures has never been conducted in Indonesia, even though the incidence of vitiligo is quite high and the success of therapy is still not optimal. So the purpose of this study is to compare the effectiveness of the two procedures in NSV patient.
The recommended dose of XELODA is 1250 mg/m2 administered orally twice daily (morning and evening; equivalent to 2500 mg/m2 total daily dose) for 2 weeks followed by a 1-week rest period given as 3-week cycles. XELODA tablets should be swallowed with water within 30 minutes after a meal. In combination with docetaxel, the recommended dose of XELODA is 1250 mg/m2 twice daily for 2 weeks followed by a 1-week rest period, combined with docetaxel at 75 mg/m2 as a 1-hour intravenous infusion every 3 weeks. Pre-medication, according to the docetaxel labeling, should be started prior to docetaxel administration for patients receiving the XELODA plus docetaxel combination. Table 17 displays the total daily dose by body surface area and the number of tablets to be taken at each dose.

Adjuvant treatment in patients with Dukes' C colon cancer is recommended for a total of 6 months, ie, XELODA 1250 mg/m2 orally twice daily for 2 weeks followed by a 1-week rest period, given as 3-week cycles for a total of 8 cycles (24 weeks).
Aqueous shampoo compositions comprise by weight (a) 5-20% of a water soluble detergent of formula RZXM where R is an acyclic hydrocarbon radical of 8-18 carbon atoms of which at least 50% comprise 12 carbon atoms, Z is an intermediate linkage (as the term is used and understood in "Surface Active Agents and Detergents," by Schwartz, Perry and Berch, Interscience Publishers, New York, 1958, Vol. II), X is an anionic group and M is a cation to neutralize the charge of X, the RZXM being such that 0-15% of the composition is a non-ampolytic detergent and 0-10% is ampholytic detergent; (b) 2-15% of an amine oxide of formula R1R2R3N-->O wherein R1 is an alkyl radical of 10-16 carbon atoms of which at least 50% have 12 carbon atoms and R2 and R3 are both methyl or ethyl, and (c) at least 60% water, the weight ratio of (b) to non-ampholytic detergent, (a) being greater than 1 : 2 and the pH of the composision being 6.5-8.5 but high enough to prevent a precipitate of interacted components (a) and (b).  Suitable non-ampholytic detergents (a) are an alkyl glyceryl ether sulphonate, an alkyl monoglyceride sulphate, a condensate of a fatty acid with a hydrolysed protein, a fatty acyl sarcosinate, a fatty acyl isethionate, or an N-methyl-N-acyl tauride, but is preferably an alkyl polyethenoxy ether sulphate containing 1-5 moles per mole ethylene oxide.  Suitable ampholytic detergents (a) are an alkyl b -iminodipropionate or an imidazole derivative of formula <FORM:0942870/C3/1> but is preferably an alkyl b -aminopropionate. When an ampholytic detergent (a) is present, part or all of the total anionic detergent content (a) may be replaced by anionic detergents which may be non-acyclic or contain no intermediate link Z; such detergents are, for example soap, alkylbenzene sulphonate, alkylphenyl polyoxyethylene sulphate or alkyl sulphonate, but alkyl sulphate is preferred.  The cation in all the anionic detergents mentioned are suitably alkali metal, magnesium, ammonium, quaternary or alkanol-ammonium, or magnesium; sodium, potassium and triethanolammonium are preferred.  R2 and R3 in the amine oxide (b) are preferably both methyl, and groups R in (a) and R1 in (b) are both preferably derived from coconut oil.  Coconut diethanolamide, sequestrants, e.g. tetrasodium ethylenediamine tetraacetate, citric acid to control the pH, ethanol, perfume and colour may also be incorporated.
OBJECTIVES: To evaluate the cytocompatibility, bioactivity, and anti-inflammatory potential of the new pre-mixed calcium silicate cement-based sealers Bioroot Flow (BrF) and AH Plus Bioceramic Sealer (AHPbcs) on human periodontal ligament stem cells (hPDLSCs) compared to the epoxy resin-based sealer AH Plus (AHP).
MATERIALS AND METHODS: Standardized discs and 1:1, 1:2, and 1:4 eluates of BrF, AHPbcs and AHP after setting were prepared. The following assays were performed: cell attachment and morphology via SEM, cell viability via a MTT assay, cell migration/proliferation via a wound-healing assay, cytoskeleton organization via immunofluorescence staining; cytokine release via ELISA; osteo/cemento/odontogenic marker expression via RT-qPCR, and cell mineralized nodule formation via Alizarin Red S staining. HPDLSCs were isolated from extracted third molars from healthy patients. Comparisons were made with hPDLSCs cultured in unconditioned (negative control) or osteogenic (positive control) culture media. Statistical significance was established at p < 0.05.
RESULTS: Both BrF and AHPbcs showed significantly positive results in the cytocompatibility assays (cell metabolic activity, migration, attachment, morphology, and cytoskeleton organization) compared with a negative control group, while AHP showed significant negative results. BrF exhibited an upregulation of at least one osteo/cementogenic marker compared to the negative and positive control groups. BrF showed a significantly higher calcified nodule formation than AHPbcs, the negative and positive control groups, while AHPbcs was higher than the negative control group. Both were also significantly higher than AHP group.
CONCLUSION: BrF and AHPbcs exhibit adequate and comparable cytocompatibility on hPDLSCs. BrF also promoted the osteo/cementogenic differentiation of hPDLSCs. Both calcium silicate-based sealers favored the downregulation of the inflammatory cytokine IL-6 and the calcified nodule formation from hPDLSCs. BrF exerted a significantly higher influence on cell mineralization than AHPbcs.
CLINICAL RELEVANCE: This is the first study to elucidate the biological properties and immunomodulatory potential of Bioroot Flow and AH Plus Bioceramic Sealer. The results act as supporting evidence for their use in root canal treatment.
Participants in the intervention arm will receive Multilevel Gaming Adherence Intervention. Participants receive Viral Combat on their mobile phones, and, for 24 weeks, game-related text messages guided by self-reported medication adherence.
With oral dosing of SOAANZ, the onset of diuresis occurs within 1 hour and the peak effect occurs during the first four hours and diuresis lasts about 6 to 8 hours.The mean increase in potassium excretion over 23 hours following a single oral dose of SOAANZ 20 mg in healthy adults was 12.7 mEq.

Edema

Torsemide has been studied in controlled trials in patients with New York Heart Association Class II to Class IV heart failure. Patients who received 10 mg to 20 mg of daily torsemide in these studies achieved significantly greater reductions in weight and edema than did patients who received placebo.

When torsemide is first administered, daily urinary sodium excretion increases for at least a week. With chronic administration, however, daily sodium loss comes into balance with dietary sodium intake. If the administration of torsemide is suddenly stopped, blood pressure returns to pretreatment levels over several days, without overshoot.

Torsemide has been administered together with β-adrenergic blocking agents, ACE inhibitors, and calcium-channel blockers. Adverse drug interactions have not been observed, and special dosage adjustment has not been necessary.
A method of ozonating a non-psychoactive cannabinoid by providing a source of non-psychoactive cannabinoid and contacting it with ozone. By contacting the non-psychoactive cannabinoid with ozone, it is converted to a psychoactive cannabinoid. In one aspect of the invention, the psychoactive cannabinoid is then isolated. The non-psychoactive cannabinoid is preferably cannabidiol (CBD), cannabinol (CBN), or cannabichromene (CBC), and the source is preferably hemp, hemp chaff, or hempseed oil. The psychoactive cannabinoid produced is tetrahydrocannabinol (THC), either Δ9-tetrahydrocannabinol or Δ8-tetrahydrocannabinol. The method of ozonating the cannabinoid is preferably in an enclosed space such as a sealed compartment. The ozone is preferably provided by an ozone generator. A composition containing the psychoactive cannabinoid produced may be used for treatment of pain, or some ailments and diseases.
Abatacept (30 mg/kg) was administered as intravenous (iv) infusion over approximately 30 minutes on Days 1 and 15, followed by 10 mg/kg (fixed dose) abatacept infusion on Day 29 and every 28 days thereafter up to and including Day 141. The dose was calculated based on screening visit weight of participants for dosing on Days 1 and 15 followed by fixed dosing as per rheumatoid arthritis label (participants weighing \<60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \>100 kg received 1000 mg) thereafter.
Emerging evidence and perspectives have pointed towards the heart playing an important role in hepatorenal syndrome (HRS), outside of conventional understanding that liver cirrhosis is traditionally considered the sole origin of a cascade of pathophysiological mechanisms directly affecting the kidneys in this context. In the absence of established heart disease, cirrhotic cardiomyopathy may occur more frequently in those with liver cirrhosis and kidney disease. It is a specific form of cardiac dysfunction characterized by blunted contractile responsiveness to stress stimuli and altered diastolic relaxation with electrophysiological abnormalities. Despite the clinical description of these potential cardiac-related complications of the liver, the role of the heart has traditionally been an overlooked aspect of circulatory dysfunction in HRS. Yet from a physiological sense, temporality (prior onset) of cardiorenal interactions in HRS and positive effects stemming from portosystemic shunting demonstrated an important role of the heart in the development and progression of kidney dysfunction in cirrhotic patients. In this review, we discuss current concepts surrounding how the heart may influence the development and progression of HRS, and the role of systemic inflammation and endothelial dysfunction causing circulatory dysfunction within this setting. The temporality of heart and kidney dysfunction in HRS will be discussed. For a subgroup of patients who receive portosystemic shunting, the dynamics of cardiorenal interactions following treatment is reviewed. Continued research to determine the unknowns in this topic is anticipated, hopefully to further clarify the intricacies surrounding the liver-heart-kidney connection and improve strategies for management.
Herein is provided a recombinant lentiviral vector preparation, in which the preparation comprises: a) an effective dose of the recombinant lentiviral vector; b) a histidine hydrochloride buffer for keeping a pH value of the preparation in the range of 6.0-8.0; and c) a carbohydrate. The recombinant lentivirus preparation in the present invention has a significantly enhanced stability due to containing the certain amount of histidine hydrochloride buffer as the non-conventional ingredient. In particular, it can be stored for a long time (e.g. more than 200 days) under the condition of an ultra-low temperature(e.g. not more than -60°C ). It can still be capable of maintaining the activities of the recombinant lentiviral vector which can meet to the requirement in use, when exposed to an organism's body temperature (for example, 37°C) or the room temperature for a longer time.
Schools randomized to the control arm receive a workshop outlining a standard-of-practice program to be used as a warm-up for 15 minutes at the beginning of each physical education class. The warm-up consists of aerobic exercises and static stretching. The workshop is designed to last one hour, and includes an explanation and demonstration of the exercises, but no video or practice time.
rinary incontinence (UI) is defined as involuntary urinary incontinence. In women with COPD, chronic coughing can often lead to UI. In this patient group, incontinence may be related to functional impairment, concomitant diseases and medications used. The aim of this study was to determine the incidence of urinary incontinence in patients with chronic obstructive pulmonary disease (COPD) and the factors that may be associated with urinary incontinence. The study included individuals who applied to the Pulmonary Diseases Policlinic of SANKO University Sani Konukoğlu Practice and Research Hospital and followed up with the diagnosis of COPD. The age, sex, height, weight, education level, smoking, exercise habits, fluid intake, medications and accompanying diseases such as heart disease, hypertension and diabetes will be recorded. Any prolapse or surgery will be questioned and noted. The disease severity will be determined by the forced expiratory volume (FEV1) value of the first second obtained from pulmonary function tests. Dyspnea score will also be determined by the Modified British Research Council (MBRC). Symptoms will be evaluated with the COPD Assessment Test (CAT). For urinary incontinence, the ICIQ-SF (International Urinary Incontinence Consultation) Questionnaire and Urinary Distress Inventory will be applied. In addition, the Leicester Cough Questionnaire will be used to assess your coughing functions, and the Activity-Self Assessment will be performed to determine the individual activity adequacy and the value of activities for individuals. All evaluations will be done only once with the help of the physiotherapist and asking the questions and recording the answers of the individual.
The invention belongs to the field of biotechnology, and provides an anti-TIGIT antibody, an anti-PVRIG antibody and a combination thereof. The invention provides compositions comprising a first antibody that binds to human TIGIT and a second antibody that binds to human PVRIG. The invention also provides a composition comprising an antibody that binds to human TIGIT. The invention also provides compositions comprising anti-PVRIG antibodies. The invention also provides anti-TIGIT antibodies. The invention also provides the use of an antigen binding domain in the preparation of an agent for use in a method of activating T cells and/or NK cells of a cancer patient. The invention also provides a bispecific antibody that binds a first target and a second target, wherein the first target is human TIGIT. The invention also provides the use of an anti-PD-L1 antibody and an anti-PVRIG antibody in the preparation of an agent for use in a method of activating T cells and/or NK cells of a cancer patient.
Subjects will receive an active electrical stimulation device (tDCS) to use up to 20 minutes daily for 4 weeks. To deliver tDCS subjects will place a strap around their forehead area.
The Home visitation program was developed in response to long wait lists for the Infant Psychiatry Program. This home visitation program intervention consists of the following components: Developmental guidance, empowerment of parents while respecting the parent-child attachment, and child centered interactional guidance. The home visitors ( a PhD student and a Masters level student) visit consenting families and gave the parents an opportunity to voice their concerns regarding their child's behaviors. They were instructed to co-construct a play that had to be child led. Home visitors facilitated this task. Parents completed the Child Behavior Checklist and Parenting Stress Index prior to and after the intervention. These home visitations occurred approximately once a month whilst the families were on the wait list for clinical assessment and treatment. Those families that were randomized in control group did not receive any intervention.

Extended description of the protocol, including information not already contained in other fields.
The goal of this study is to evaluate if the DNA-Ad vaccine that targets both the liver and blood stages of the malaria life cycle is safe and protective, in hopes to develop a vaccine to prevent infection and/or lessen the severity of disease caused by the P. falciparum malaria parasite. More specifically, this DNA-Ad vaccine contains a liver stage antigen (circumsporozoite protein) and an antigen (apical membrane antigen 1) that is present in both the liver and blood stages designed to prevent infection by killing the majority of developing parasites in the liver and to prevent severe disease and death should break-through blood stage infections occur.

This study is an open-label, Phase 1/2a study designed to assess the safety, immunogenicity, and efficacy of a DNA-Ad vaccine in healthy adults who are Ad5 seropositive or seronegative. The vaccinated study group will consist of up to 20 healthy, malaria-naïve adults aged 18 to 50 years, who have been previously screened to meet inclusion and exclusion criteria and will receive three priming doses of the DNA vaccine and a single dose of the boosting component, an adenovirus-vectored vaccine to be given 4 months after the last dose of DNA. Follow up visits will occur after each immunization. The control group will consist of six non-immunized subjects that will participate in a challenge to assure that vaccinated subjects were indeed exposed to P. falciparum. Subjects in both the immunized and control cohorts will receive malaria challenge. Subjects will be assessed for development of parasitemia by daily blood smears and will be closely observed in hotel after the challenge. Subjects will then be followed periodically and have the final in-person visit twelve weeks after the challenge, followed by annual contact by phone, email, or mailings up to five years after the first dose of immunization per FDA recommendation.
TTM is a persistent impulse control disorder in which the individual acts on urges to pull out his or her own hair. Onset typically occurs by adolescence, and TTM is often associated with significant functional impairment and distress. CBT is a type of psychotherapy designed to change problematic behaviors and thinking. It includes self-monitoring of hair-pulling urges and homework assignments to practice the use of cognitive and behavioral strategies.

Participants are assigned randomly to receive either CBT or AC for 8 weeks. Participants assigned to CBT receive weekly 1-hour sessions of CBT for 8 weeks; participants assigned to AC receive 6 telephone contacts and 2 in-person sessions for 8 weeks. After 8 weeks, CBT participants who respond to treatment enter Phase II, which lasts an additional 8 weeks and includes 4 in-person maintenance sessions. AC participants who are still symptomatic after 8 weeks are offered CBT.
PURPOSE:To prepare a pigment having excellent storage stability and water resistance and exhibiting a good adhesion to the human skin by adding an aq. soln. of a polyvalent metal salt and an acid to an aq. soln. of a water-sol. N-acylaspartic acid salt wherein an inorg. pigment has been suspended. CONSTITUTION:At least one polyvalent metal salt and at least one acid are added to an aq. soln. of a water-sol. N-acylaspartic acid salt, wherein an inorg. pigment has been suspended, to give an inorg. pigment coated with a polyvalent metal salt of N-acylaspartic or aspartic acid of the formula (wherein RCO is a residue of capric, lauric, myristic, palmitic, stearic, or oleic acid; and M is H, Mg, Ca, Co, Zn, Al, Ti, Fe, or Zr). The coating material, the polyvalent metal salt of N-acylaspartic acid, is formed by a combination of a water-sol. salt of N-acylaspartic acid with a water-sol. polyvalent metal salt.
Participants will receive amplification with hearing aids. Bilateral open-fit hearing aids will be fitted. Participants will be required to use the hearing aids for at least 2 hours daily for 12 months.
Thyroxine, a key regulator of metabolic pathways, plays a pivotal role in glucose metabolism and the maintenance of glucose homeostasis. In clinical practice, L-thyroxine replacement therapy is commonly prescribed for patients with hypothyroidism. However, the specific effects of L-thyroxine and thyroidectomy (TX) on glucose levels remain an area of interest and investigation. In this study, 20 rats were divided into two groups (n=10 per group). The TX group (male and female rats) underwent thyroidectomy for 4 weeks. After 4 weeks, male and female thyroidectomized rats received L-thyroxine (10 μg/100 g/day, intraperitoneally) for 4 weeks. The rats' weights were monitored weekly post-surgery. Compared to the initial level, thyroidectomy resulted in weight loss, whereas L-thyroxine replacement therapy normalized the weight loss induced by thyroidectomy. Additionally, thyroidectomy led to impaired glucose levels, which were restored to normal levels with L-thyroxine treatment. These findings underscore the impact of thyroid function on glucose metabolism and highlight the potential therapeutic role of L-thyroxine.
Patients receive pralatrexate IV over 3-5 minutes and docetaxel IV on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
A method calculates a score representing cardiovascular condition progression cardiovascular condition using feature data comprising cardiovascular image features from a population including a background group and a target group at a later stage of the condition. Contrastive principal component analysis is applied between feature data from the background and target groups to obtain a transformation into a reduced representation space, which is applied to the population feature data to determine positions of each individual in the space. Trajectories are determined in the space between the target and background groups by connecting the positions. The score is calculated as a distance along the one of the trajectories on which the position of an individual lies. Another method calculates a contribution of each of the plurality of features to the transformation, and determines a plurality of features having the highest contributions. Other methods derive models for calculating the score by fitting.
Will occur over two separate study visits after screening. Eligible male subjects with MetSyn will complete an oral ET-1 Inhibition during one visit and an oral placebo in the other visit. Subjects will also undergo 3 Tesla MRI scanning and an intravenous catheter, and will complete an Oral Glucose Tolerance Test during the study visits. More details under Study Description.